Vericel (VCEL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.04
- Estimate
- -$0.03
- Surprise
- +250.0%
- Revenue (period 2026-06-30)
- $77.5M
- Score today
- 6.2/10
Revenue source: xbrl.
How the report landed
Vericel (VCEL) beat the -$0.03 estimate with diluted EPS of $0.04 — a large 250.0% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates VCEL Hold at 6.2/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +250.0% surprise compares with a +285.3% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: Matricel GmbH
- Concentration risk — Supplier: MediWound
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $38.34
- Price target
- $52.70
- Stop
- $36.23
- Upside to target
- +37.5%
- Reward-to-risk
- 5.8:1
The stock trades at 79.9× trailing but 45.3× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 26 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
VCEL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.96B
- P/E (fwd)
- 45.3
- P/E (ttm)
- 79.9
- 52-week range
- $28.95–$49.32
- Off 52-week high
- 22.3%
- RSI (14)
- 26
- Volume vs avg
- 1.06×
- Score today
- 6.2/10